Compare DexCom, Inc. (DXCM) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Silvercorp Metals Inc. Common Shares — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Silvercorp Metals Inc. Common Shares trades at $9.5 (market cap $2.21B). The key difference: DexCom, Inc. is far larger — about 14.5× Silvercorp Metals Inc. Common Shares's market cap, and Silvercorp Metals Inc. Common Shares pays a 0.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| DXCM | SVM | |
|---|---|---|
Market Cap | $32.09B | $2.21B |
Volume | 3,819,730 | 1,113,327 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $15.71 |
52-Week Low | $54.84 | $6.09 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $1.94B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
